BMRN:NGS-BioMarin Pharmaceutical Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 66.83

Change

0.00 (0.00)%

Market Cap

USD 14.69B

Volume

0.84M

Analyst Target

USD 111.27
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-4.62 (-1.13%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

-1.89 (-0.26%)

USD 78.92B
ARGX argenx NV ADR

+24.08 (+3.88%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-1.13 (-0.48%)

USD 30.22B
MRNA Moderna Inc

+0.39 (+0.92%)

USD 16.10B
UTHR United Therapeutics Corporatio..

-0.94 (-0.26%)

USD 15.91B
RPRX Royalty Pharma Plc

-0.09 (-0.35%)

USD 15.05B
SMMT Summit Therapeutics PLC

-0.77 (-4.22%)

USD 13.43B
INCY Incyte Corporation

+2.28 (+3.27%)

USD 13.41B
INSM Insmed Inc

-3.24 (-4.64%)

USD 12.50B

ETFs Containing BMRN

GNOG:LSE Global X Genomics & Biote.. 4.08 % 0.00 %

+0.10 (+0.97%)

USD 9.55M
BIS ProShares UltraShort Nasd.. 1.91 % 0.95 %

+0.08 (+0.97%)

USD 4.38M
BTEC:SW iShares Nasdaq US Biotech.. 1.63 % 0.00 %

+0.06 (+0.97%)

N/A
SPX4:LSE SPDR® S&P 400 US Mid Cap.. 0.59 % 0.00 %

+0.65 (+0.97%)

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.05 (+0.97%)

USD 0.04B
LABS 0.00 % 0.45 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
FCVT First Trust SSI Strategic.. 0.00 % 0.95 %

+0.14 (+0.97%)

USD 0.08B
EASI 0.00 % 0.75 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.16 (+0.97%)

USD 0.07B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+0.97%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.02 (0.97%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-3.55 (0.97%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

+0.05 (+0.97%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.97%)

N/A
UBIO 0.00 % 0.95 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

+0.30 (+0.97%)

N/A
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

+1.78 (+0.97%)

N/A
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

+2.15 (+0.97%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.02 (+0.97%)

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.04 (0.97%)

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.67% 27% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.67% 27% F 55% F
Trailing 12 Months  
Capital Gain -30.72% 46% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.72% 46% F 24% F
Trailing 5 Years  
Capital Gain -20.64% 68% D+ 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.64% 68% D+ 35% F
Average Annual (5 Year Horizon)  
Capital Gain -1.71% 46% F 34% F
Dividend Return -1.71% 45% F 30% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15.69% 98% N/A 83% B
Risk Adjusted Return -10.88% 37% F 27% F
Market Capitalization 14.69B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.26 19% 25%
Price/Book Ratio 2.35 48% 44%
Price / Cash Flow Ratio 79.97 1% 4%
Price/Free Cash Flow Ratio 24.49 3% 15%
Management Effectiveness  
Return on Equity 6.25% 95% 69%
Return on Invested Capital 2.96% 83% 62%
Return on Assets 3.00% 95% 77%
Debt to Equity Ratio 11.98% 54% 69%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector